Nitipong Permpalung, MD, MPH, discusses how early remdesivir may reduce graft loss and cardiovascular events after COVID-19 in kidney transplant recipients.
Nitipong Permpalung, MD, MPH
Advertisement
Nitipong Permpalung, MD, MPH, is an associate director of the Johns Hopkins Transplant Research Center.
Articles by Nitipong Permpalung, MD, MPH
Early remdesivir treatment was associated with lower graft loss and cardiovascular events in kidney transplant recipients, noted Nitipong Permpalung, MD, MPH.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ICER Draft Flags High Cost of New Hypertension Drug Class
2
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
3
Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care
4
What Comes After Anti-VEGF in Wet AMD: Arshad Khanani, MD
5